

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 10739

EXHIBIT F

AMERICAN PHARMACEUTICAL ASSOCIATION

The National Professional Society of Pharmacists

September 27, 1973

Director
Defense Supply Agency
Attention: DSAH-XA
Cameron Station
Alexandria, VA 22314

Dear Sir:

It is my understanding that the Defense Personnel Support Center headquartered in Philadelphia, Pennsylvania has specific responsibility within the Defense Supply Agency for the procurement of medical supplies -- and specifically drugs and drug products -- to fill the needs of the U. S. Department of Defense.

From time to time officials affiliated with the DPSC have described the procedures employed within that agency which are intended and desired to ensure that satisfactory quality drugs and drug products are purchased by them. In describing these procedures, the DPSC has indicated that a key feature in this process is the determination of the capabilities and qualifications of individual manufacturers -- such determination by DPSC is being made on the basis of certain criteria including inspection of the manufacturing plant facilities, testing of the pertinent firm's drug products within the DPSC's laboratory, and other appropriate considerations to enable such judgments to be made.

At various times, DPSC staff have referred to the fact that as a result of operation of the above described procedure, lists of drug company names (either alone or in association with specific drugs) have been developed which may be described as "lists of acceptable or qualified bidders" and/or "lists of unacceptable or unqualified bidders."

Under provisions of the regulation entitled, "Availability to the Public of Official Information," which was recently published in the Federal Register (38 FR 24206-24210) I am hereby requesting copies of any and all the above described lists of acceptable and unacceptable bidders for drug contracts over the past approximately five-year period.

Your assistance and cooperation in this regard will be greatly appreciated.

Sincerely,

Edward G. Feldmann, Ph.D.
Associate Executive Director
for Scientific Affairs

ehb

2215 CONSTITUTION AVENUE, N.W., WASHINGTON, D.C. 20037 • (202) 628-4410

CABLE ADDRESS: AMPHARMA